Literature DB >> 24452423

Calcitonin gene-related peptide and migraine with aura: A systematic review.

Jakob M Hansen1, Messoud Ashina2.   

Abstract

BACKGROUND: Calcitonin gene-related peptide (CGRP) is a key molecule in migraine pathophysiology. Most studies have focused on CGRP in relation to migraine without aura (MO). About one-third of migraine patients have attacks with aura (MA), and this is a systematic review of the current literature on CGRP and MA.
METHODS: We performed a systematic literature search on MEDLINE for reports of CGRP and MA, covering basic science, animal and human studies as well as randomized clinical trials.
RESULTS: The literature search identified 594 citations, of which 38 contained relevant, original data. Plasma levels of CGRP in MA patients are comparable to MO, but CGRP levels varied among studies. A number of animal studies, including knock-ins of familial hemiplegic migraine (FHM) genes, have examined the relationship between CGRP and cortical spreading depression. In patients, CGRP does not trigger migraine in FHM, but is a robust trigger of migraine-like headache both in MA and MO patients. The treatment effect of CGRP antagonists are well proven in the treatment of migraine, but no studies have studied the effect specifically in MA patients.
CONCLUSION: This systematic review indicates that the role of CGRP in MA is less studied than in MO. Further studies of the importance of CGRP for auras and migraine are needed. © International Headache Society 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  CGRP; Calcitonin gene-related peptide; migraine with aura; spreading depression; systematic review

Year:  2014        PMID: 24452423     DOI: 10.1177/0333102413520084

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  6 in total

Review 1.  What is the evidence for the use of corticosteroids in migraine?

Authors:  Y W Woldeamanuel; A M Rapoport; R P Cowan
Journal:  Curr Pain Headache Rep       Date:  2014-12

2.  Induction of calcitonin gene-related peptide expression in rats by cortical spreading depression.

Authors:  Yan Wang; Anne E Tye; Junli Zhao; Dongqing Ma; Ann C Raddant; Fan Bu; Benjamin L Spector; Nolan K Winslow; Minyan Wang; Andrew F Russo
Journal:  Cephalalgia       Date:  2016-11-12       Impact factor: 6.292

3.  Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody.

Authors:  Agustin Melo-Carrillo; Rodrigo Noseda; Rony-Reuven Nir; Aaron J Schain; Jennifer Stratton; Andrew M Strassman; Rami Burstein
Journal:  J Neurosci       Date:  2017-06-22       Impact factor: 6.167

4.  Rimegepant for the treatment of migraine.

Authors:  Amnon A Berger; Ariel Winnick; Austin H Carroll; Alexandra Welschmeyer; Nathan Li; Marc Colon; Antonella Paladini; Giovanni F Ramírez; Jamal Hasoon; Elyse M Cornett; Jaehong Song; Giustino Varrassi; Adam M Kaye; Alan D Kaye; Latha Ganti
Journal:  Health Psychol Res       Date:  2022-10-12

5.  Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors.

Authors:  Agustin Melo-Carrillo; Andrew M Strassman; Rony-Reuven Nir; Aaron J Schain; Rodrigo Noseda; Jennifer Stratton; Rami Burstein
Journal:  J Neurosci       Date:  2017-09-29       Impact factor: 6.167

Review 6.  An Evidence-Based Review of Fremanezumab for the Treatment of Migraine.

Authors:  Ivan Urits; Gavin Clark; Daniel An; Bredan Wesp; Rebecca Zhou; Ariunzaya Amgalan; Amnon A Berger; Hisham Kassem; Anh L Ngo; Alan D Kaye; Rachel J Kaye; Elyse M Cornett; Omar Viswanath
Journal:  Pain Ther       Date:  2020-03-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.